secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001437749-23-021937
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology Q2 net income $2.1M, down from $9.4M YoY; revenue flat at $51.6M
--------------------------------------------------------------------------------

- GAAP net income $2.1M ($0.05/diluted share) vs $9.4M ($0.21) Q2 2022; non-GAAP adj net income $4.6M ($0.10).
- Product revenue from NERLYNX $51.6M, slightly up from $51.3M YoY; royalty revenue fell to $3.0M from $8.2M.
- Net cash from operations positive $3.3M vs -$13.9M Q2 2022; cash & securities $74.4M at June 30.
- FY 2023 guidance: product revenue $205-210M, net income $20-24M; Q3 product revenue guided $51-53M.
- Pipeline milestones: Phase II alisertib in small cell lung cancer H2 2023; FDA meeting Q4 for HR+ HER2- breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/0001437749-23-021937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/pbyi20230731_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-021937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer